4-苄氧基-2-羟基-3-甲基-苯乙酮 | 73640-74-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-苄氧基-2-羟基-3-甲基-苯乙酮
• 英文名称: 4'-Benzyloxy-2'-hydroxy-3'-methylacetophenone
• 英文别名: 1-(2-hydroxy-3-methyl-4-phenylmethoxyphenyl)ethanone
• CAS: 73640-74-1
• 化学式: C₁₆H₁₆O₃
• mdl: MFCD00010752
• 分子量: 256.301
• InChiKey: PWGVUHPMXRYALX-UHFFFAOYSA-N

物化性质

• 熔点：
  88-90 °C(lit.)
• 沸点：
  422.3±40.0 °C(Predicted)
• 密度：
  1.163±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.187
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2914509090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
: 4′-Benzyloxy-2′-hydroxy-3′-methylacetophenone
Product name
CAS-No. : 73640-74-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S37/39 Wear suitable gloves and eye/face protection.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C16H16O3
Molecular Weight : 256,30 g/mol
Component Concentration
4'-Benzyloxy-2'-hydroxy-3'-methylacetophenone
CAS-No. 73640-74-1 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 88 - 90 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-苄氧基-2-羟基-3-甲基-苯乙酮 在 硝酸 、 sodium hydride 、 溶剂黄146 、 sodium nitrite 作用下， 以 甲苯 、 mineral oil 为溶剂， 反应 0.25h， 生成 7-benzyloxy-4-hydroxy-8-methyl-3-nitrochromen-2-one
  参考文献：
  名称：

  演示LC3A和LC3B适配器接口的可配性

  摘要：

  自噬是许多基于溶酶体的胞质货物降解途径的统称。自噬的关键成分是Atg8家族蛋白的成员，几乎参与了该过程的所有步骤，从自噬体形成到与溶酶体的选择性融合。在这项研究中，我们显示人类Atg8家族蛋白LC3A和LC3B的同源成员可通过小分子抑制剂新霉素进行药物治疗。在LC3A二氢新生物素复合物的晶体结构的支持下，进行了4-羟基香豆素核心支架的结构-活性关系（SAR）研究。

  DOI：

  10.1021/acs.jmedchem.0c01564
• 作为产物：
  描述：

  2,6-二羟基甲苯 在 三氟化硼乙醚 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 24.0h， 生成 4-苄氧基-2-羟基-3-甲基-苯乙酮
  参考文献：
  名称：

  与丝裂霉素A相关的吲哚-2-酮（羟吲哚）的合成

  摘要：

  合成了含有丝裂霉素A结构的前两个环的官能团的羟吲哚（吲哚-2-酮）。由于羟吲哚基团或其衍生物对亲核攻击具有抗性，尝试使用羟吲哚基团构建第三个环的尝试未成功。注意到3-甲基-5-硝基苯-1,2,4-三醇的不寻常的甲基化，得到（E）-3,6-二羟基-2-甲基-1,4-苯醌4-甲氧基亚胺N-氧化物。描述了新颖的吲哚形成。

  DOI：

  10.1039/p19880001823

文献信息

• AUTOPHAGY INHIBITORS
  申请人：Deutsches Krebsforschungszentrum

  公开号：EP3184514A1

  公开（公告）日：2017-06-28

  A compound, which is a) a tetrahydrotriazine derivative of the formula (I), a tautomer, a pharmaceutically acceptable salt, a solvate or hydrate thereof, were the symbols have the meanings given in the description, or b) a coumarin derivative of the formula (II), a tautomer, a pharmaceutically acceptable salt, solvate or hydrate thereof, were the symbols have the meanings given in the description, is useful in a therapeutical method for inhibiting autophagy in a cell and for the treatment of cancer.

  一种化合物，其为 a) 公式（I）的四氢三唑衍生物， 其互变体，药学上可接受的盐，溶剂合物或水合物，其中符号的含义如描述中所给， 或者 b) 公式（II）的香豆素衍生物， 其互变体，药学上可接受的盐，溶剂合物或水合物，其中符号的含义如描述中所给， 在细胞中抑制自噬并用于癌症治疗的治疗方法中是有用的。
• Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and
  申请人：Pharmacia & Upjohn Company

  公开号：US05703075A1

  公开（公告）日：1997-12-30

  This invention relates to compounds of Formula I ##STR1## which are useful in association with a pharmaceutical carrier as antiatherosclerotic agents. In addition, various compounds of Formula I are useful inhibitors of cell proliferation.

  这项发明涉及公式I的化合物，这些化合物在与药用载体一起作为抗动脉粥样硬化药剂时是有用的。此外，公式I的各种化合物是细胞增殖的有效抑制剂。
• [EN] BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE<br/>[FR] DERIVES DE L'IMIDAZOLE BICYCLIQUES DIRIGES CONTRE LES FLAVIVIRIDAE
  申请人：GENELABS TECH INC

  公开号：WO2005012288A1

  公开（公告）日：2005-02-10

  Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

  揭示了用于治疗黄病毒科病毒感染的化合物、组合物和方法。
• Pyrone derivatives as protease inhibitors and antiviral agents
  申请人：Warner-Lambert Company

  公开号：US05808062A1

  公开（公告）日：1998-09-15

  The present invention relates to novel tri- and tetrasubstituted pyrones and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The pyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized pyrones and of related structures.

  本发明涉及新颖的三取代和四取代吡喃酮及相关结构，能有效抑制HIV天冬氨酸蛋白酶，阻止HIV的感染性。这些吡喃酮衍生物在开发治疗细菌和病毒感染以及疾病，包括艾滋病的疗法中是有用的。本发明还涉及多功能吡喃酮及相关结构的合成方法。
• (Benzodioxan, benzofuran or benzopyran) derivatives having fundic
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06133277A1

  公开（公告）日：2000-10-17

  The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk.sup.1 is C.sub.1-6 alkanediyl optionally substituted with hydroxy, C.sub.1-4 alkyloxy or C.sub.1-4 alkylcarbonyloxy; --Z.sup.1 --Z.sup.2 -- is a bivalent radical; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, C.sub.1-6 alkyl, hydroxy, halo and the like; or when R.sup.1 and R.sup.2 are on adjacent carbon atoms, R.sup.1 and R.sup.2 taken together may form a bivalent radical; R.sup.4 is hydrogen or C.sub.1-6 alkyl; A is a bivalent radical of formula --NR.sup.6 --Alk.sup.2 -- (b-1), or --Npiperidinyl--(CH.sub.2).sub.m (b-2) wherein m is 0 or 1; R.sup.5 is a radical of formula ##STR1## wherein n is 1 or 2; p.sup.1 is 0, and p.sup.2 is 1 or 2; or p.sup.1 is 1 or 2, and p.sup.2 is 0; X is oxygen, sulfur or .dbd.NR.sup.9 ; Y is oxygen or sulfur; R.sup.7 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl or phenylmethyl; R.sup.8 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl phenyl or phenylmethyl; R.sup.9 is cyano, C.sub.1-6 alkyl, C.sub.3-6 cyclo-alkyl, C.sub.1-6 alkyloxycarbonyl or aminocarbonyl; R.sup.10 is hydrogen or C.sub.1-6 alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

  本发明涉及化合物的公式(I)，其立体化学异构体形式，N-氧化物形式或药物可接受的酸加成盐形式，其中Alk.sup.1是C.sub.1-6烷二基可选地被羟基，C.sub.1-4烷氧基或C.sub.1-4烷基羧酸基取代; --Z.sup.1 --Z.sup.2 --是一个二价基团; R.sup.1，R.sup.2和R.sup.3各自独立地选择自氢，C.sub.1-6烷基，羟基，卤素等; 或者当R.sup.1和R.sup.2在相邻的碳原子上时，R.sup.1和R.sup.2可以组成一个二价基团; R.sup.4是氢或C.sub.1-6烷基; A是公式--NR.sup.6--Alk.sup.2--(b-1)或--Npiperidinyl--(CH.sub.2).sub.m (b-2)的二价基团，其中m为0或1; R.sup.5是公式##STR1##的基团，其中n为1或2; p.sup.1为0，p.sup.2为1或2; 或者p.sup.1为1或2，p.sup.2为0; X是氧，硫或.dbd.NR.sup.9; Y是氧或硫; R.sup.7是氢，C.sub.1-6烷基，C.sub.3-6环烷基，苯基或苯甲基; R.sup.8是C.sub.1-6烷基，C.sub.3-6环烷基，苯基或苯甲基; R.sup.9是氰基，C.sub.1-6烷基，C.sub.3-6环烷基，C.sub.1-6烷氧羰基或氨基羰基; R.sup.10是氢或C.sub.1-6烷基; Q是一个二价基团。公开了制备所述产品的过程，包含所述产品的制剂以及其作为药物的用途，特别是用于治疗与胃底松弛受损相关的疾病。